Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
304 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07410520 | PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL. | recruiting | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07405125 | Safety of Robotic Surgery for GISTs at Special Anatomic Sites | recruiting | N/A | 182 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 12, 2026 |
| clinicaltrials |
| NCT07396454 | Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib | recruiting | Phase 2 | 39 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07391826 | Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX | not yet recruiting | Phase 2 | 48 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07389356 | Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL | not yet recruiting | N/A | 70 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Feb 5, 2026 | clinicaltrials |
| NCT07372339 | Comparison of Breast Sensory Recovery Between Conventional and Endoscopic Nipple-Sparing Mastectomy Combined With Prepectoral Implant Reconstruction | not yet recruiting | N/A | 170 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jan 28, 2026 | clinicaltrials |
| NCT07371247 | Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy | enrolling by invitation | Early Phase 1 | 65 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07347288 | SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell Lymphoma | not yet recruiting | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07331454 | Robotic vs Laparoscopic Gastrectomy for cT4a Gastric Cancer | not yet recruiting | Phase 3 | 335 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07330895 | Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors | not yet recruiting | Early Phase 1 | 19 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jan 9, 2026 | clinicaltrials |
| NCT07315035 | QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer | not yet recruiting | Phase 2 | 74 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07309211 | Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT | recruiting | — | 25 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07294625 | A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | Early Phase 1 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07277452 | Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer(NOTABLE-309) | not yet recruiting | Phase 2 | 156 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07263386 | A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer(ARTEMIS-GC3) | recruiting | Phase 2 | 460 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07263425 | Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis | recruiting | Phase 2 | 26 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06295549 | Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 11 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT06838910 | Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma | recruiting | Phase 2 | 20 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07185035 | An Exploratory Clinical Study on the Safety and Efficacy of Autologous NK Cells in the Treatment of Pulmonary Nodules | recruiting | Early Phase 1 | 24 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07250347 | AI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT | recruiting | — | 8,000 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07250360 | Adjuvant Chemotherapy for High-Risk Pathologic Stage I Non-Squamous NSCLC | completed | — | 2,072 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Nov 26, 2025 | clinicaltrials |
| NCT06958705 | Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy | recruiting | Phase 2 | 79 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07240194 | The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study | recruiting | Phase 2 | 24 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT07208981 | Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL | recruiting | Phase 2 | 169 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT06925555 | Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS | not yet recruiting | Phase 2 | 25 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07195799 | Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL | recruiting | Phase 2 | 180 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT07156643 | A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma. | not yet recruiting | Phase 2 | 46 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07134101 | Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)(SMARTi-RC01) | not yet recruiting | Phase 2 | 138 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Aug 29, 2025 | clinicaltrials |
| NCT07131501 | A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 48 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT06497738 | A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma | recruiting | — | 112 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07126678 | Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma | recruiting | N/A | 15 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07117812 | Feasibility and Safety of Laparoscopic Purse-string Suture Clamp and Multi-functional Seal Cap for Totally Laparoscopic Radical Total Gastrectomy | not yet recruiting | N/A | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Aug 15, 2025 | clinicaltrials |
| NCT06979921 | PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale BREAST Cancers, PERCEIVE-BREAST | active not recruiting | — | 496 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07113496 | RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies | not yet recruiting | Phase 1 | 27 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT07113613 | Prospective Study on Exemption of Tumor Bed Boost Radiotherapy for pCR Patients After Breast Conserving Surgery With Neoadjuvant Therapy | recruiting | Phase 2 | 150 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07113964 | QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD) | not yet recruiting | Phase 2 | 79 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07108595 | Efficacy and Safety of T-DXd in Patients With HER2-positive and HER2-low Metastatic Breast Cancer: a Real-world Study | completed | — | 142 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT04570410 | Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma | completed | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT05123625 | Prognostic Effect of Whether Doing PLND During RC for High-risk NMIBC(PLND-Less) | recruiting | N/A | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT07092111 | Efficacy of Auricular Acupuncture Therapy in the Prevention of CIPN in Breast Cancer | unknown | N/A | 110 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06427252 | The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM | active not recruiting | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07065435 | RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study | recruiting | Phase 2 | 74 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT07056010 | Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy | recruiting | N/A | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06048913 | Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age | completed | Phase 2 | 56 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT07050524 | Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial | not yet recruiting | Phase 2 | 80 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT06895447 | Robotic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Therapy | recruiting | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06939439 | Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer | active not recruiting | Phase 3 | 416 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06977828 | A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC | not yet recruiting | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT04963088 | Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT)(TALENT) | completed | Phase 1 / Phase 2 | 65 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07036731 | A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing | recruiting | N/A | 428 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 25, 2025 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials